Making an RNA Detour Around an Undruggable Target

Some cancer-driving proteins offer few ways for conventional drugs to target, leaving patients with limited options even when researchers understand what fuels their tumors. Remix Therapeutics is approaching that problem by developing oral small molecules that alter RNA processing to reduce production of those proteins. Pete Smith, co-founder and CEO of Remix, discusses the company’s experimental MYB-targeting therapy, the early evidence in adenoid cystic carcinoma, and whether changing how cells process RNA could open a new route to previously elusive cancer targets.